Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,179
archived clinical trials in
Anxiety

A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Bridgewater, NJ
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Brooklyn, NY
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Brooklyn, NY
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Cincinnati, OH
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Muskogee, OK
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Muskogee, OK
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Philadelphia, PA
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
American Fork, UT
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
American Fork, UT
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Norfolk, VA
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated:  11/9/2012
Clinical Research Facility
mi
from
Seattle, WA
A Study in Pediatric Patients With Generalized Anxiety Disorder
A Double-Blind, Efficacy and Safety Study of Duloxetine Versus Placebo in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
Status: Enrolling
Updated: 11/9/2012
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Status: Enrolling
Updated:  12/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
A Collaborative Care Program to Improve Treatment of Depression and Anxiety Disorders in Cardiac Patients
Status: Enrolling
Updated: 12/12/2012
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia
Status: Enrolling
Updated:  1/18/2013
Boston University
mi
from
Boston, MA
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia
Status: Enrolling
Updated: 1/18/2013
Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia
Status: Enrolling
Updated:  1/18/2013
Southern Methodist University
mi
from
Dallas, TX
Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety
Placebo-Controlled Evaluation of the Efficacy of Yohimbine Hydrochloride for Enhancing the Effects of CBT for Social Phobia
Status: Enrolling
Updated: 1/18/2013
Southern Methodist University
mi
from
Dallas, TX
Click here to add this to my saved trials
Lifestyle Interventions for Generalized Anxiety Disorder
Lifestyle Interventions for Generalized Anxiety Disorder
Status: Enrolling
Updated:  1/18/2013
BU Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Lifestyle Interventions for Generalized Anxiety Disorder
Lifestyle Interventions for Generalized Anxiety Disorder
Status: Enrolling
Updated: 1/18/2013
BU Center for Anxiety and Related Disorders, Boston University
mi
from
Boston, MA
Click here to add this to my saved trials
Lifestyle Interventions for Generalized Anxiety Disorder
Lifestyle Interventions for Generalized Anxiety Disorder
Status: Enrolling
Updated:  1/18/2013
Anxiety Research and Treatment Program, SMU Department of Psychology
mi
from
Dallas, TX
Lifestyle Interventions for Generalized Anxiety Disorder
Lifestyle Interventions for Generalized Anxiety Disorder
Status: Enrolling
Updated: 1/18/2013
Anxiety Research and Treatment Program, SMU Department of Psychology
mi
from
Dallas, TX
Click here to add this to my saved trials
Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder
Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder(ASD) Undergoing Medical Imaging Procedures
Status: Enrolling
Updated:  2/13/2013
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder
Effect of a Social Script iPAD Application for Children With Autism Spectrum Disorder(ASD) Undergoing Medical Imaging Procedures
Status: Enrolling
Updated: 2/13/2013
Children's Hospital of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated:  2/14/2013
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated: 2/14/2013
Walter Reed National Military Medical Center
mi
from
Bethesda, MD
Click here to add this to my saved trials
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated:  2/14/2013
Pain Management Service
mi
from
Philadelphia, PA
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated: 2/14/2013
Pain Management Service
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated:  2/14/2013
Brooke Army Medical Center & US Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Regional Anesthesia Military Battlefield Pain Outcomes Study
Regional Anesthesia in Combat Trauma Improves Pain Disability Outcomes
Status: Enrolling
Updated: 2/14/2013
Brooke Army Medical Center & US Army Institute of Surgical Research
mi
from
Fort Sam Houston, TX
Click here to add this to my saved trials
The Effects of Lavender Aromatherapy on Reducing Stress and Anxiety During MRI Procedures.
The Effects of Lavender Aromatherapy on the Reduction of Stress and Anxiety During MRI Procedures. A Randomized Study Comparing the Use of Lavender Aromatherapy to no Aromatherapy.
Status: Enrolling
Updated:  3/13/2013
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
The Effects of Lavender Aromatherapy on Reducing Stress and Anxiety During MRI Procedures.
The Effects of Lavender Aromatherapy on the Reduction of Stress and Anxiety During MRI Procedures. A Randomized Study Comparing the Use of Lavender Aromatherapy to no Aromatherapy.
Status: Enrolling
Updated: 3/13/2013
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)
Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)
Status: Enrolling
Updated:  3/18/2013
The Hartford Hospital
mi
from
Hartford, CT
Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)
Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)
Status: Enrolling
Updated: 3/18/2013
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Therapist Assisted Online Treatment for Anxiety
Therapist Assisted Online Treatment for Anxiety
Status: Enrolling
Updated:  3/19/2013
Counseling and Wellness Center, University of Florida
mi
from
Gainesville, FL
Therapist Assisted Online Treatment for Anxiety
Therapist Assisted Online Treatment for Anxiety
Status: Enrolling
Updated: 3/19/2013
Counseling and Wellness Center, University of Florida
mi
from
Gainesville, FL
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Birmingham Research Group, Inc
mi
from
Birmingham, AL
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Birmingham Research Group, Inc
mi
from
Birmingham, AL
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Dr. Joseph H. Rodd
mi
from
Carson, CA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Dr. Joseph H. Rodd
mi
from
Carson, CA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Sun Valley Research
mi
from
Imperial, CA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Sun Valley Research
mi
from
Imperial, CA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Irvine Center for Clinical Research
mi
from
El Toro, CA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Irvine Center for Clinical Research
mi
from
El Toro, CA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Sharp Mesa Vista Hospital, Clinical Research Department
mi
from
San Diego, CA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Sharp Mesa Vista Hospital, Clinical Research Department
mi
from
San Diego, CA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Elite Clinical Trials
mi
from
Wildomar, CA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Elite Clinical Trials
mi
from
Wildomar, CA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Florida Clinical Research Center LLC
mi
from
Maitland, FL
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Sarkis Clinical Trials
mi
from
Gainesville, FL
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Kolin Research Group
mi
from
Winter Park, FL
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Kolin Research Group
mi
from
Winter Park, FL
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Atlanta Center for Medical Research
mi
from
Atlanta, GA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Atlanta Center for Medical Research
mi
from
Atlanta, GA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Institute for Behavioral Medicine
mi
from
Smyrna, GA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Institute for Behavioral Medicine
mi
from
Smyrna, GA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Midwest Research Group
mi
from
St. Charles, MO
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Premier Psychiatric Group, LLC
mi
from
Lincoln, NE
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Premier Psychiatric Group, LLC
mi
from
Lincoln, NE
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Center for Psychiatry and Behavioral Medicine, Inc.
mi
from
Las Vegas, NV
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Weill Medical College of Cornell University
mi
from
New York, NY
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Weill Medical College of Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Columbia University, NY State Psychiatric Institute
mi
from
New York, NY
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Columbia University, NY State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Finger Lakes Clinical Research
mi
from
Rochester, NY
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Finger Lakes Clinical Research
mi
from
Rochester, NY
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Richmond Behavioral Associates
mi
from
Staten Island, NY
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Richmond Behavioral Associates
mi
from
Staten Island, NY
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Duke University Medical Center, Duke Child and Family Study Center
mi
from
Durham, NC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Duke University Medical Center, Duke Child and Family Study Center
mi
from
Durham, NC
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
mi
from
Cincinnati, OH
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
University of Cincinnati, Department of Psychiatry and Behavioral Neuroscience
mi
from
Cincinnati, OH
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
University Hospitals of Cleveland Medical Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Professional Psychiatric Services
mi
from
Mason, OH
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Professional Psychiatric Services
mi
from
Mason, OH
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
North Star Research
mi
from
Middleburg Heights, OH
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
North Star Research
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
IPS Research Company
mi
from
Oklahoma City, OK
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Coastal Carolina Research Center
mi
from
Mt Pleasant, SC
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Coastal Carolina Research Center
mi
from
Mt Pleasant, SC
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
Research Strategies of Memphis, LLC
mi
from
Memphis, TN
Click here to add this to my saved trials
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated:  3/27/2013
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
A Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Tolerability of SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP).
Status: Enrolling
Updated: 3/27/2013
FutureSearch Clinical Trials, LP
mi
from
Dallas, TX
Click here to add this to my saved trials